J&J reports declining spine sales in Q3 – what to expect in Q4

Written by Mackenzie Garrity | November 20, 2017 | Print  |

Although reporting $19.7 billion total sales in the third quarter of 2017, Johnson & Johnson's spine division saw a decline in sales, according to Market Realist.

Here's what you need to know.


1. With the emergence of competitors, such as Medtronic, Zimmer Biomet and Stryker, Johnson and Johnson's spine sales and market share have continued to decline in the U.S.


2. Gaps in Johnson & Johnson's spine portfolio have also influenced declines in sales. However, the company claimed internal and macroeconomic factors as reasons for weak sales.


3. While the device company estimates the U.S. and North American spine markets are experiencing lower procedure volumes, Johnson & Johnson's spine sales were positive in Asian and Latin American markets.


4. In the upcoming quarter, Johnson & Johnson plans to launch devices from its recent acquisitions. Johnson & Johnson acquired Sentio, a company that markets spine surgery technology, in June 2017.


5. To fill the gaps in its spine portfolio, Johnson & Johnson also acquired Interventional Spine Expandable Cage Technology, and in late October the company's DePuy Synthes subsidiary launched its Viper Prime System and Concorde Clear MIS Discectomy Tool.


More articles on devices and implants:
ReWalk Robotics opens $7.2M public offering — 5 takeaways
5 principles for medtech companies to increase revenue
Zimmer Biomet, K2M, Medicrea & more: 6 device company notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months